BIOGEN INC. · Biotech

BIIB

Low riskNext report: Due any day

View price ↗

The short version

A high-quality, profitable business with steady sales. Institutions are adding.

Going well

Profitable every year for 10 years
Brings in more cash than it spends

Money moves

No insider buying or selling in the last 30 days
Institutions added 6% to their holdings in the quarter ending June 2026 (532 bought, 371 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$252.27+0.6% that day

Company value: $37.2B; Share price times all shares
Price vs profit (P/E): 27.1x; You pay about $27 for each $1 of yearly profit
Price vs sales: 3.7x; Company value is 3.7 times a year of sales
Cash vs value: 9%; Cash as a share of company value
Debt vs value: 17%; Debt as a share of company value

From BIIB's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Mar '26

$2.5B+1.9% vs a year earlier

Jun '23Tap a barMar '26

Last 12 months: $9.9B, up 1.2% from the 12 months before. Over 5 years, sales shrank about 6.0% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of BIIB. Starting points are the company's recent numbers.

Sales growth+1% a yearRecently: +1.2% a yearProfit margin14%Last 12 months: 13.8%P/E at the end27xToday: 27.1x. Many steady companies trade at 12x to 25xShare count change0% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$10.4B

Profit in 5 years$1.5B

Price these guesses point to$267.41+6.0% vs $252.27 todayAbout +1.2% a year, before dividends

What today's price needs: with a 14% margin and a 27x P/E, sales could shrink about 0.2% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

4/4Strong

PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.13.1%
PassProfitable every yearSteady profits, not one good year.10 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$2.1B
PassShare count not growingNot diluting owners. Falling means buybacks.+0.8% in 3 years

Revenue: $9.9B; +2.2% vs prior year
5-year growth: -6.0%/yr; revenue, per year
Total debt: $6.3B
Current ratio: 2.68x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, debt under half of equity, gross margin 40%+. A checklist is a starting point for research, not a verdict.